2 news · updated Jul 20, 2026

Novartis buys Myricx

2026-07-19

Novartis faces drug pipeline test with valuation premium in focus

Novartis investors await critical second-half drug trial readouts for key candidates to justify its premium valuation against looming patent expiries. Analysts warn failures could significantly impact

reuters · 2026-07-19 22:04 UTC

2026-07-05

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

Novartis agreed to acquire UK biotech Myricx Bio for up to $1.5 billion to expand its antibody-drug conjugate cancer treatments, with the deal set to close in the second half of 2026.

reuters · 2026-07-05 22:26 UTC

Novartis buys Myricx

Novartis faces drug pipeline test with valuation premium in focus

Novartis to acquire UK-based Myricx Bio for up to $1.5 billion

Media coverage (2)

Related topics